Clinical Trial: A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn

U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07886684) titled 'A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn' on Oct. 15.

Brief Summary: This study is the first time BNT3210 will be tested in people. It will evaluate different dose levels to find suitable doses and to understand how safe the treatment is and how it may help people with advanced solid tumors.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors

Intervention: DRUG: BNT3210

Intravenous infusion

Recruitment Status: NOT_YET_RECRUITING

Sponsor: BioNTech SE

Pu...